Operating profit before amortization: cormedix.com (CRMD)

Brandmark of CorMedix Inc (CRMD)

The success of CorMedix Inc. (CRMD) is based on the expansion of Defencath across dialysis centers, supported by a staff of highly qualified researchers. Absolute operating profit demonstrates the result of this synergy, where 253.37 serves as the current parameter value. The stable operation of contract manufacturing lines and equipment calibration guarantee zero downtime, ensuring the further growth of the company's operating metrics.

CRMD: CorMedix Operating profit EBITDA 11/23/2025 - 11/12/2026

CorMedix - analytical breakdowns and key metrics (CRMD)

- stock value and consensus price forecast:
Market Chart CorMedix Therapeutics|CRMD - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization CorMedix|CRMD - Enterprise Value
- balance sheet net asset value indicators:
Share Book Value CorMedix|CRMD - Book Capitalization|Market-to-Book Ratio cormedix.com|CRMD - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio CorMedix Inc.|CRMD - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio CorMedix Inc|CRMD - Company Aggregate Debts|Debts to Net Assets CorMedix|CRMD - Company Long-Term Debt|Short-Term Debt CorMedix|Immediate Liquidity Ratio cormedix.com
- earnings and valuation multiples information:
CRMD - Company Net Income|Company Profit Forecast CorMedix Inc.|CRMD - P/E Multiple|Projected Price to Earnings cormedix.com|CRMD - Price/Earnings to Growth Ratio|Company Value to EBITDA CorMedix|CRMD - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year CorMedix|CRMD - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months cormedix.com|CRMD - Earnings growth in current year|Expected net earnings per share growth next year CorMedix Inc.
Summary company analytics:CRMD CorMedix Therapeutics
Mass-produced product of cormedix.com

The implementation of the Inertia drug in dialysis centers generates sustainable demand and long-term business margins for CorMedix Inc. (CRMD). This trend directly determines the values of the metric reflecting cash flow from operating activities. The indicator measures the net volume of operating funds before deducting depreciation and interest on loans. This allows for an assessment of the model's efficiency regardless of the debt load. By analyzing the total operating profit before depreciation, an investor can see the real solvency of CorMedix Inc. (CRMD).

Competitors of CorMedix Inc. (CRMD)

Operating income before deduction of amortization Summit Pharma (SMMT)|MRNA - Profit before payment of interest, taxes and amortization|PCVX (vaxcyte.com) - Operating profit before amortization|TARS: Operating profit EBITDA|Profit before deduction of interest, taxes, depreciation and amortization MCRB (Seres Therapeutics Inc.)|SPRO (Spero) - Operating profit EBITDA|Profit before interest, taxes and amortization Scynexis SCYX|Operating profit EBITDA ANTX|Operating profit before deduction of amortization polypid.com PYPD|LakeShore Biopharma - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization ITRM (Iterum Therapeutics PLC)|BiomX Ltd - Operating profit EBITDA|Operating income before deduction of amortization Soligenix, Inc. SNGX|60degreespharma.com (SXTP) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization oragenics.com (OGEN)|Profit before payment of interest, taxes and amortization OpGen